Asthma Control-A "Patient Follow up Programme" Maintenance and Reliever Therapy in a Single Inhaler

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00524641
First received: August 30, 2007
Last updated: July 8, 2009
Last verified: July 2009
  Purpose

To investigate the change in patient's asthma symptom control using ACQ scores after 4 to 6 weeks of Symbicort Turbuhaler (budesonide/ formoterol) in SMART approach.


Condition
Asthma

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Patient Follow-up Program to Assess Asthma Control in Patients Using Symbicort® as Maintenance and Relief Therapy in a Single Inhaler (Symbicort® SMART: Budesonide/Formoterol 160/4.5 Mcg, 1 or 2 Inhalations x 2 Times Plus Additional Inhalations as Needed)

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Enrollment: 1254
Study Start Date: July 2007
Study Completion Date: April 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Hospital out-patient departments and private clinics in all areas of Vietnam

Criteria

Inclusion Criteria:

  • Asthma patients from both sexes, age 18 or older
  • Have already been on Symbicort SMART treatment
  • Willing to give written informed consents to participate in the program.

Exclusion Criteria:

  • Patients who are not willing to give written informed consent
  • Patients in emergency care for asthma at ICUs or COPD patients are excluded from the program.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00524641

Locations
Vietnam
Research Site
Hanoi, Vietnam
Research Site
Ho Chi Minh City, Vietnam
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Dinh Ngoc SY, MD TB and Lung Disease Hospital, Hanoi
Study Chair: Tran Van Ngoc, MD, PhD Cho Ray Hospital
Study Chair: Nguyen Hong Duc Pharm Ngoc Thach Hospital
Study Chair: Do Van Dung, MD, PhD Ho Chi Minh City Univ of Medicine and Pharmacist
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00524641     History of Changes
Other Study ID Numbers: NIS-RVN-SYM-2007/1, NIS-R84-AST-2007/3
Study First Received: August 30, 2007
Last Updated: July 8, 2009
Health Authority: Vietnam: Ho Chi Minh City Health Service

Keywords provided by AstraZeneca:
Asthma
Symbicort
NIS

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on September 30, 2014